Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Futura Medical ( (GB:FUM) ) has provided an announcement.
Futura Medical reported its financial results for the first half of 2025, highlighting challenges with slower-than-expected sales of its lead product, Eroxon, resulting in a significant revenue drop to £1.0m compared to £7.0m in the previous year. The company is undergoing a strategic review to address these challenges, including cost-cutting measures and exploring new commercial opportunities to extend its cash runway. Despite the current financial setbacks, Futura remains focused on progressing its development plans for Eroxon Intense and WSD4000, with the potential to create shareholder value through additional partnerships and distribution arrangements.
The most recent analyst rating on (GB:FUM) stock is a Buy with a £140.00 price target. To see the full list of analyst forecasts on Futura Medical stock, see the GB:FUM Stock Forecast page.
More about Futura Medical
Futura Medical plc is a consumer healthcare group specializing in the development and global commercialization of innovative and clinically proven sexual health products. Their lead product, Eroxon®, is a topical gel treatment for erectile dysfunction (ED) that is available over the counter. The company also develops products like WSD4000 for women’s sexual dysfunction, aiming to address significant unmet needs in the sexual health market.
Average Trading Volume: 1,194,034
Technical Sentiment Signal: Sell
Current Market Cap: £10.01M
See more insights into FUM stock on TipRanks’ Stock Analysis page.